Insider · CIK 0001311210
Patrick Machado
director
Files at ADVM (Adverum Biotechnologies, Inc.), XENE (Xenon Pharmaceuticals Inc.), RCUS (Arcus Biosciences, Inc.), ALMS (ALUMIS INC.), SLRN (ACELYRIN, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 30, 2025 | ALMS ALUMIS INC. | AGrant or award Stock Option (Right to Buy)derivative | +49,800 | $0.00 | $0 | 49,800 | Aug 1, 2025 |
| Jun 17, 2025 | ADVM Adverum Biotechnologies, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +10,450 | $0.00 | $0 | 10,450 | Jun 20, 2025 |
| Jun 17, 2025 | ADVM Adverum Biotechnologies, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +3,140 | $0.00 | $0 | 3,140 | Jun 20, 2025 |
| Jun 10, 2025 | RCUS Arcus Biosciences, Inc. | AGrant or award Common Stock | +13,300 | $0.00 | $0 | 38,600 | Jun 12, 2025 |
| Jun 10, 2025 | RCUS Arcus Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +38,300 | $0.00 | $0 | 38,300 | Jun 12, 2025 |
| Jun 5, 2025 | XENE Xenon Pharmaceuticals Inc. | AGrant or award Share Option (Right to Buy)derivative | +17,012 | $0.00 | $0 | 17,012 | Jun 6, 2025 |
| Jun 5, 2025 | XENE Xenon Pharmaceuticals Inc. | AGrant or award Restricted Share Unitsderivative | +2,645 | $0.00 | $0 | 2,645 | Jun 6, 2025 |
| May 21, 2025 | SLRN ACELYRIN, Inc. | DDisposition to issuer Common Stockindirect: See footnote | -14,675 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | ALMS ALUMIS INC. | AGrant or award Common Stockindirect: By Trust | +7,064 | - | - | 7,064 | May 23, 2025 |
| May 21, 2025 | SLRN ACELYRIN, Inc. | DDisposition to issuer Director Stock Option (right to buy)derivative | -92,158 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | ALMS ALUMIS INC. | AGrant or award Stock Option (Right to Buy)derivative | +44,364 | - | - | 44,364 | May 23, 2025 |
| May 21, 2025 | SLRN ACELYRIN, Inc. | DDisposition to issuer Director Stock Option (right to buy)derivative | -23,243 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | ALMS ALUMIS INC. | AGrant or award Stock Option (Right to Buy)derivative | +11,189 | - | - | 11,189 | May 23, 2025 |
| May 21, 2025 | SLRN ACELYRIN, Inc. | DDisposition to issuer Director Stock Option (right to buy)derivative | -28,675 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | ALMS ALUMIS INC. | AGrant or award Stock Option (Right to Buy)derivative | +41,499 | - | - | 41,499 | May 23, 2025 |
| May 21, 2025 | SLRN ACELYRIN, Inc. | DDisposition to issuer Director Stock Option (right to buy)derivative | -86,206 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | ALMS ALUMIS INC. | AGrant or award Stock Option (Right to Buy)derivative | +13,804 | - | - | 13,804 | May 23, 2025 |
| May 21, 2025 | SLRN ACELYRIN, Inc. | DDisposition to issuer Director Stock Option (right to buy)derivative | -40,567 | - | - | 0 | May 23, 2025 |
| May 21, 2025 | ALMS ALUMIS INC. | AGrant or award Stock Option (Right to Buy)derivative | +19,528 | - | - | 19,528 | May 23, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.